Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages 182-190, November 2010

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study

  • M.A. Banerji

      Affiliations

    • SUNY Health Science Center, Brooklyn, NY, USA
    • ,
  • D. Purkayastha

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • B.H. Francis

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • Corresponding Author InformationCorresponding author at: Novartis Pharmaceuticals Corporation, One Health Plaza, Bldg. 501-Room 336, East Hanover, NJ 07936-1080, USA. Tel.: +1 862 7788337; fax: +1 862 7782345.

Received 11 March 2010; received in revised form 14 June 2010; accepted 17 June 2010. published online 26 July 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0168-8227(10)00324-4

doi:10.1016/j.diabres.2010.06.022

Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages 182-190, November 2010

Article Tools

* Image Usage & Resolution